This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 13.64% and 6.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
by Zacks Equity Research
One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 17.50% and 11.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 0% and 0.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Q2 Earnings Miss Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of -27.91% and 0.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 53.57% and 3.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of -25% and 1%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 20% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (FNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -466.67% and 2.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -10% and 0.23%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -34.62% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Best Breakout Stocks to Invest In Ahead of 2023
by Tirthankar Chakraborty
KORU Medical Systems (KRMD), Asure Software (ASUR) and YPF Sociedad Anonima (YPF) have been selected as the breakout stocks for today.
KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 40% and 11.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Soars 7.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
DexCom (DXCM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 0% and 4.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Repro Med Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 16.67% and 4.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repro Med Systems, Inc. (KRMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 5.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of -7.14% and 6.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -5% and 8.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Repro Med Systems, Inc. (KRMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repro Med Systems, Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 10.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Repro Med Systems, Inc. (KRMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repro Med Systems, Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 10.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?